Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Chemother ; 22(5): 355-7, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21123160

RESUMEN

The aim of this observational prospective study was to compare the effect of fosfomycin tromethanol (FT) and carbapenems (meropenem or imipenem cilastatin) in the treatment of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli-related complicated lower urinary tract infection (CLUTI). Inclusion criteria were: patients who were aged >18 yr with dysuria or problems with frequency or urgency in passing urine; those with >20 leukocytes/mm³ in urine microscopy and culture-proven ESBL-producing carbapenem or FT-sensitive E. coli in the urine (>105 cfu/mm³); no leukocytosis or fever; and who were treated with ft (oral 3 g sachet x 1 every other night, three times) or carbapenems between march 2005 and January 2006 in our outpatient clinic and hospital. A total of 47 CLUTI attacks in 47 patients (27 FT group, 20 carbapenem group) were observed prospectively. Clinical and microbiological success in the carbapenem and ft groups was similar (19/20 vs 21/27 and 16/20 vs 16/27 p>0.05). Drug acquisition costs were significantly lower in the FT group (p<0.001). Although it is not a randomized controlled study, these data show that ft may be a suitable, effective and cheap alternative in the treatment of ESBL-producing E. coli-related CLUTI.


Asunto(s)
Antibacterianos/uso terapéutico , Carbapenémicos/uso terapéutico , Infecciones por Escherichia coli/tratamiento farmacológico , Escherichia coli/efectos de los fármacos , Fosfomicina/uso terapéutico , Infecciones Urinarias/tratamiento farmacológico , beta-Lactamasas/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Carbapenémicos/economía , Farmacorresistencia Bacteriana , Escherichia coli/enzimología , Infecciones por Escherichia coli/microbiología , Femenino , Fosfomicina/economía , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Estudios Prospectivos , Infecciones Urinarias/microbiología , Adulto Joven
2.
Hum Reprod Genet Ethics ; 14(2): 20-6, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-19024333

RESUMEN

All prospective studies and purposes to improve cure and create a race that would be exempt of various diseases and disabilities are generally defined as eugenic procedures. They aim to create the "perfect" and "higher" human being by eliminating the "unhealthy" prospective persons. All of the supporting actions taken in order to enable the desired properties are called positive eugenic actions; the elimination of undesired properties are defined as negative eugenics. In addition, if such applications and approaches target the public as a whole, they are defined as macro-eugenics. On the other hand, if they only aim at individuals and/or families, they are called micro-eugenics. As generally acknowledged, Galton re-introduced eugenic proposals, but their roots stretch as far back as Plato. Eugenic thoughts and developments were widely accepted in many different countries beginning with the end of the 19th to the first half of the 20th centuries. Initially, the view of negative eugenics that included compulsory sterilizations of handicapped, diseased and "lower" classes, resulted in tens of thousands being exterminated especially in the period of Nazi Germany. In the 1930s, the type of micro positive eugenics movement found a place within the pro-natalist policies of a number of countries. However, it was unsuccessful since the policy was not able to become effective enough and totally disappeared in the 1960s. It was no longer a fashionable movement and left a deep impression on public opinion after the long years of war. However, developments in genetics and its related fields have now enabled eugenic thoughts to reappear under the spotlight and this is creating new moral dilemmas from an ethical perspective.


Asunto(s)
Eugenesia/historia , Política de Planificación Familiar/historia , Política de Salud/historia , Principios Morales , Ética Médica , Eugenesia/tendencias , Alemania , Política de Salud/tendencias , Historia del Siglo XIX , Historia del Siglo XX , Historia Antigua , Humanos , Esterilización Involuntaria/historia , Turquía
3.
Neurocirugia (Astur) ; 19(3): 267-71, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18654727

RESUMEN

Hemi-facial spasm, facial paralysis, and trigeminal neuralgia are prevailing signs and symptoms with which physicians have been coping for thousands of years. Ibn Sina (known as Avicenna in the West), who was among the leading figures during medieval ages and influenced the upcoming periods in the Eastern and Western hemispheres for long time, focused also on these crucial problems. In his principal medical work, the Canon of Medicine, Avicenna underlined the significance of wry mouth-related disorders and wrote a precise chapter over this topic with the heading "Laqve." However, the term "laqve" is usually accepted only as facial paralysis in most of historical texts. Further detailed analysis of the text reveals that, all the above-mentioned signs and symptoms are considered under the same heading. Therefore, the descriptions articulated by famous physician Avicenna pose great merit from the point of historical view of neurological sciences. The main aim of this article is to reintroduce essential parts of the text by adding comments over specific descriptions, and consequently, to make the text more comprehensible for today's scientists.


Asunto(s)
Parálisis Facial , Manuscritos Médicos como Asunto , Medicina Arábiga/historia , Boca/inervación , Médicos , Parálisis Facial/diagnóstico , Parálisis Facial/patología , Parálisis Facial/terapia , Historia Medieval , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA